Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015

February 05, 2015

LAVAL, Quebec, Feb. 5, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Tuesday, February 24, 2015 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2014 fourth quarter and full year.

The dial-in number to participate on this call is (877) 876-8393, confirmation code 73880342.  International callers should dial (973) 200-3961, confirmation code 73880342. A replay will be available approximately two hours following the conclusion of the conference call to May 24, 2015, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 73880342.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

Valeant Pharmaceuticals International, Inc.

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-to-announce-2014-fourth-quarter-and-full-year-results-on-february-24-2015-300031108.html

SOURCE Valeant Pharmaceuticals International, Inc.